---
ID: 3199
post_title: >
  U.S. jury finds Immunosyn ex-CEO Ferrone
  guilty of fraud
author: Staff Writer
post_date: 2016-04-30 01:30:10
post_excerpt: ""
layout: post
permalink: >
  https://www.whenitson.com/u-s-jury-finds-immunosyn-ex-ceo-ferrone-guilty-of-fraud/
published: true
original_cats:
  - domesticNews
original_title:
  - >
    U.S. jury finds Immunosyn ex-CEO Ferrone
    guilty of fraud
original_link:
  - >
    http://feeds.reuters.com/~r/Reuters/domesticNews/~3/a5VzG74-E7k/us-immunosyn-lawsuit-idUSKCN0XR00N
canonical_url:
  - >
    http://feeds.reuters.com/~r/Reuters/domesticNews/~3/a5VzG74-E7k/us-immunosyn-lawsuit-idUSKCN0XR00N
---
 [ad_1]
<br><div id="articleText">
<span id="midArticle_start"/>

<span class="focusParagraph" readability="4"><p><span class="articleLocatio&lt;/span&gt;n">A U.S. federal jury found former Immunosyn Corp Chief Executive Stephen Ferrone guilty on Friday of fraudulently misleading investors, U.S. securities regulators said. </span></p></span><span id="midArticle_0"/><p>The U.S. Securities and Exchange Commission in 2011 had charged California-based Immunosyn with misleading investors about the regulatory status of the company's sole product, a drug derived from goat blood called SF-1019, that was intended to treat a variety of ailments. (<a href="http://reut.rs/1UmHoaK">reut.rs/1UmHoaK</a>)</p><span id="midArticle_1"/><p>The SEC said the jury on Friday found that Ferrone's "statements in multiple annual reports, quarterly reports, current reports, press releases, speeches, and interviews fraudulently misled investors."</p><span id="midArticle_2"/>
        
        <span class="first-article-divide"/><p>“We are pleased with the jury’s finding that Stephen Ferrone defrauded Immunosyn’s investors with misleading statements in the company’s filings and press releases and his own speeches and interviews," Andrew Ceresney, director of the SEC'S Division of Enforcement said in a statement. </p><span id="midArticle_3"/>
        
        <span class="second-article-divide"/><p>The SEC'S complaint had alleged that Immunosyn misleadingly stated in various public filings from 2006 to 2010 that its controlling shareholder, Argyll Biotechnologies LLC, either planned to seek or had sought U.S. regulatory approval for human clinical trials for SF-1019.</p><span id="midArticle_4"/>
        
        <span class="third-article-divide"/><span id="midArticle_5"/><p> (Reporting by Subrat Patnaik and Ismail Shakil in Bengaluru; Editing by Leslie Adler)</p><span id="midArticle_6"/></div>
<br>[ad_2]
<br><a href="http://feeds.reuters.com/~r/Reuters/domesticNews/~3/a5VzG74-E7k/us-immunosyn-lawsuit-idUSKCN0XR00N">Source </a>